Dulles, Virginia, March 2, 2012 – IBA Molecular North America, Inc. (IBA) has announced the
introduction of SureStart™, an innovative peer review system for NaF PET/CT bone imaging programs.
SureStart is designed to help sites effectively establish NaF PET/CT imaging services by fostering quality
assurance, staff capability and confidence, and enhanced value to the referring physician community.
SureStart provides direct educational support for PET/CT interpreters with a web-enabled system
providing expert peer review for equivocal or challenging NaF PET/CT cases. With minimal configuration
and installation requirements, SureStart delivers expert feedback, within approximately 24 hours, on
interpretive agreement, as well as technical quality aspects, such as windowing, use of CT co-
registration, MIP evaluation, etc. Complementing this service is an introductory educational package
dedicated to providing reading physicians with the basics of NaF PET/CT imaging to support
interpretation. Included is a narrated reader training presentation, instructional videos on windowing
techniques and image processing, illustrative case studies, as well as a NaF PET/CT reporting template.
Implementation of SureStart can assist imaging centers in providing quality service, delivering value to
their referring community, and experiencing accelerated program growth.
SureStart is an important adjunct to IBA’s NaF Education Best Practices Framework, an all-inclusive
education and marketing plan to successfully launch and grow NaF PET/CT bone imaging programs
within the referring community. By taking advantage of IBA’s support services, clients are poised for more
rapid and sustainable growth in their NaF programs. IBA’s market leadership in 18F Sodium Fluoride is
evidence that these programs work.
SureStart is part of IBA’s PETLinQ suite of products, all of which are designed to support and enhance
PET imaging programs. PETLinQ IQ is an innovative PET educational web portal, available to all IBA
customers. PETLinQ WD is a cost-effective, web-enabled image distribution and archive system,
designed to improve connectivity between the imaging site and the referring community. For more
information on SureStart, including IBA’s complimentary introductory peer review offering, contact your
regional IBA Clinical Account Executive, or go to http://www.iba-molecular.com
ABOUT IBA
IBA Molecular North America, Inc. is part of Ion Beam Applications S.A. (IBA SA) Molecular Tracers business
unit. IBA Molecular is a global developer, manufacturer and distributor of radiopharmaceutical products and
supporting services used in molecular imaging. IBA Molecular has engineered a strong and unique product
portfolio and pipeline of diagnostic tracers aimed at contributing to the development of the global trend towards
personalized medicine and making molecular imaging a major discipline in healthcare. The company also
provides educational, technical and marketing support to medical specialists worldwide to help better respond
to patient needs. IBA SA develops and markets leading-edge technologies, pharmaceuticals and tailor-made
solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging its scientific expertise, IBA
SA is also active in the field of industrial sterilization and ionization. Listed on the pan-European stock
exchange EURONEXT, IBA SA is included in the BelMid Index. (IBA:Reuters IBAB.BR and Bloomberg
IBAB.BB).
Please visit www.iba-molecular.com and www.iba-molecular.com for more information about IBA Molecular
and IBA SA.
CONTACT:
IBA
Randall Mastrangelo
Vice President, Marketing
IBA Molecular North America, Inc.
Randall.Mastrangelo@iba-group.com